Comparison of Pharmacokinetic Characteristics and Safety Between JW Amlodipine(R) Tablet 5 mg and Novarsc(R) Tablet 5 mg in Healthy Male Volunteers.
10.12793/jkscpt.2013.21.2.95
- Author:
Yo Han KIM
1
;
Hyeong Seok LIM
;
Sang Heon CHO
;
Jong Lyul GHIM
;
Sangmin CHOE
;
Jin Ah JUNG
;
Kyun Seop BAE
Author Information
1. Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, Seoul, Korea. ksbae@amc.seoul.kr
- Publication Type:Original Article ; Randomized Controlled Trial
- Keywords:
Amlodipine;
Pharmacokinetics;
Safety;
Healthy volunteers
- MeSH:
Amlodipine;
Calcium Channels;
Cross-Over Studies;
Electrocardiography;
Healthy Volunteers;
Humans;
Hypertension;
Male*;
Mass Spectrometry;
Pharmacokinetics;
Physical Examination;
Plasma;
Vital Signs
- From:Journal of Korean Society for Clinical Pharmacology and Therapeutics
2013;21(2):95-103
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Amlodipine is a third-generation dihydropyridine calcium channel blocker, which has proven to be a useful drug against hypertension or angina. METHODS: This randomized, open-label, two-period, two-treatment, single-dose, crossover study was conducted in twenty healthy male volunteers. Subjects were administered 5 mg of the test or reference formulation. After 2-week washout period, the other formulation was administered. Blood samples were collected up to 144 hours after drug administration, and plasma amlodipine concentrations were determined by validated liquid chromatography-tandem mass spectrometry. Drug safety was assessed using measurement of vital signs, physical examinations, laboratory test, electrocardiograms, and adverse event monitoring. RESULTS: All subjects were completed this study. The geometric mean ratios of Cmax and AUClast were 1.078 (90 % CI, 0.968 - 1.200) and 1.095 (90 % CI, 1.011 - 1.186), respectively. There were no serious adverse events were reported by both formulations. CONCLUSION: This study showed the test and reference formulations had similar pharmacokinetics and safety profiles.
